EAST WINDSOR, NJ -- (MARKET WIRE) -- January 31, 2007 -- NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal treatments based on the NexACT® drug delivery technology, today announced that its collaborator, Novartis, has commenced dosing of patients in the Phase 3 clinical trials for NM100060, a topical treatment for onychomycosis (nail fungus). NexMed signed an exclusive, worldwide licensing agreement with Novartis in September 2005, under which Novartis has assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060.
